TISLELIZUMAB

Search structure
Synonyms:
Status: Phase 3
Entry Type: Antibody
Molecule Category: UNKNOWN
UNII: 0KVO411B3N

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Programmed cell death protein 1 inhibitor
Primary Target
programmed cell death 1 (CD279)

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Esophageal Neoplasms 4 D004938 ClinicalTrials
Neoplasms 4 D009369 ClinicalTrials
Stomach Neoplasms 4 D013274 ClinicalTrials
Stomach Neoplasms 4 D013274 ClinicalTrials
Esophageal Neoplasms 4 D004938 ClinicalTrials
Adenocarcinoma 4 D000230 ClinicalTrials
Carcinoma, Hepatocellular 3 D006528 ClinicalTrials
Small Cell Lung Carcinoma 3 D055752 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Hodgkin Disease 3 D006689 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 3 D016403 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Hodgkin Disease 3 D006689 ClinicalTrials
Cholangiocarcinoma 3 D018281 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Rectal Neoplasms 3 D012004 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Squamous Cell Carcinoma of Head and Neck 3 D000077195 ClinicalTrials
Cholangiocarcinoma 3 D018281 ClinicalTrials
Nasopharyngeal Carcinoma 3 D000077274 ClinicalTrials
Rectal Neoplasms 3 D012004 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Carcinoma 2 D002277 ClinicalTrials
Glioblastoma 2 D005909 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Biliary Tract Neoplasms 2 D001661 ClinicalTrials
Colorectal Neoplasms 2 D015179 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Lung Neoplasms 2 D008175 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Nasopharyngeal Neoplasms 2 D009303 ClinicalTrials
Colonic Neoplasms 2 D003110 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials
Colorectal Neoplasms 2 D015179 ClinicalTrials
Kidney Neoplasms 2 D007680 ClinicalTrials
Liver Neoplasms 2 D008113 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Granuloma, Lethal Midline 2 D006103 ClinicalTrials
Colonic Neoplasms 2 D003110 ClinicalTrials
Astrocytoma 2 D001254 ClinicalTrials
Colorectal Neoplasms 2 D015179 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Oligodendroglioma 2 D009837 ClinicalTrials
Carcinoma, Renal Cell 2 D002292 ClinicalTrials
Uterine Cervical Neoplasms 2 D002583 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Colorectal Neoplasms 2 D015179 ClinicalTrials
Thyroid Neoplasms 2 D013964 ClinicalTrials
Lymphoma, Non-Hodgkin 2 D008228 ClinicalTrials
Prostatic Neoplasms 2 D011471 ClinicalTrials
Triple Negative Breast Neoplasms 2 D064726 ClinicalTrials
Carcinoma, Renal Cell 2 D002292 ClinicalTrials
Biliary Tract Neoplasms 2 D001661 ClinicalTrials
Adenocarcinoma of Lung 2 D000077192 ClinicalTrials
Uterine Cervical Neoplasms 2 D002583 ClinicalTrials
Digestive System Neoplasms 1 D004067 ClinicalTrials
Endometrial Neoplasms 1 D016889 ClinicalTrials
Ascites 1 D001201 ClinicalTrials
Lymphoma, T-Cell 1 D016399 ClinicalTrials
Carcinoma, Pancreatic Ductal 1 D021441 ClinicalTrials
Leukemia 1 D007938 ClinicalTrials
Lymphoma, T-Cell, Peripheral 1 D016411 ClinicalTrials

Cross References

Resources Reference
CAS NUMBER 1858168-59-8
ChEMBL CHEMBL4297840
FDA SRS 0KVO411B3N
Guide to Pharmacology 9592
CONTENTS